Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04815187 · ClinicalTrials.gov registry record · Phase 4
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
A Phase 4 study of Allergic Rhinitis and Vertigo, sponsored by House Ear Institute.
- Active
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT04815187 is a Phase 4 study of Allergic Rhinitis and Vertigo that is active but no longer recruiting, run by House Ear Institute. The registered enrollment target is 39 participants, below the 104-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04815187, a Phase 4 study of Allergic Rhinitis and Vertigo, is active but no longer recruiting, sponsored by House Ear Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Montelukast
Study Locations (2)
California
- House Ear Clinic - Los Angeles
- House Institute Foundation - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2021-06-07 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04815187
The ClinicalTrials.gov registry entry for NCT04815187 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (62% lower). The listed sponsor is House Ear Institute, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04815187 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04815187 about?
NCT04815187 is a clinical study titled "Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease". The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.
What is the current status of trial NCT04815187?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2021-06-07. Estimated completion is 2025-12-31.
What conditions does trial NCT04815187 study?
This clinical trial studies the following conditions: Allergic Rhinitis, Vertigo, Meniere Disease.
What interventions are being tested in trial NCT04815187?
The interventions under investigation include: Placebo (DRUG), Montelukast (DRUG).
Who is sponsoring clinical trial NCT04815187?
This trial is sponsored by House Ear Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04815187 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
-
The Effect of Cetirizine on Bronchoconstriction
COMPLETED · Phase 4
-
Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
COMPLETED · Phase 4
-
Comparability and Standardization of Controlled Allergen Challenge Facilities
COMPLETED · Phase 4
-
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
COMPLETED · Phase 4
-
Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.